379 related articles for article (PubMed ID: 28386699)
21. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.
Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E
Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304
[TBL] [Abstract][Full Text] [Related]
22. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
[TBL] [Abstract][Full Text] [Related]
23. Binding modes of chain arylpiperazines to 5-HT1a, 5-HT2a and 5-HT7 receptors.
Bielenica A; Kozioł AE; Struga M
Mini Rev Med Chem; 2013 Aug; 13(10):1516-39. PubMed ID: 24568298
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
25. Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling.
Buchborn T; Schröder H; Höllt V; Grecksch G
J Psychopharmacol; 2014 Jun; 28(6):545-52. PubMed ID: 24785760
[TBL] [Abstract][Full Text] [Related]
26. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
27. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
De Gregorio D; Comai S; Posa L; Gobbi G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886063
[TBL] [Abstract][Full Text] [Related]
28. LSD and ketanserin and their impact on the human autonomic nervous system.
Olbrich S; Preller KH; Vollenweider FX
Psychophysiology; 2021 Jun; 58(6):e13822. PubMed ID: 33772794
[TBL] [Abstract][Full Text] [Related]
29. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
Pierce PA; Peroutka SJ
J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
[TBL] [Abstract][Full Text] [Related]
30. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
[TBL] [Abstract][Full Text] [Related]
31. Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives.
Fiorella D; Rabin RA; Winter JC
Psychopharmacology (Berl); 1995 Oct; 121(3):357-63. PubMed ID: 8584618
[TBL] [Abstract][Full Text] [Related]
32. Targeting Serotonin 5-HT
Kantrowitz JT
CNS Drugs; 2020 Sep; 34(9):947-959. PubMed ID: 32783116
[TBL] [Abstract][Full Text] [Related]
33. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
[TBL] [Abstract][Full Text] [Related]
34. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
[TBL] [Abstract][Full Text] [Related]
35. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).
Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Hoang K; Wallach J; Halberstadt AL
Drug Test Anal; 2016 Sep; 8(9):891-902. PubMed ID: 26456305
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
[TBL] [Abstract][Full Text] [Related]
37. Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music.
Barrett FS; Preller KH; Herdener M; Janata P; Vollenweider FX
Cereb Cortex; 2018 Nov; 28(11):3939-3950. PubMed ID: 29028939
[TBL] [Abstract][Full Text] [Related]
38. The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers.
Wingen M; Kuypers KP; Ramaekers JG
Psychopharmacology (Berl); 2007 Feb; 190(3):391-400. PubMed ID: 17124621
[TBL] [Abstract][Full Text] [Related]
39. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.
Benneyworth MA; Smith RL; Barrett RJ; Sanders-Bush E
Psychopharmacology (Berl); 2005 Jun; 179(4):854-62. PubMed ID: 15645221
[TBL] [Abstract][Full Text] [Related]
40. Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala.
Hornboll B; Macoveanu J; Rowe J; Elliott R; Paulson OB; Siebner HR; Knudsen GM
J Psychopharmacol; 2013 Oct; 27(10):903-14. PubMed ID: 23824248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
